Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

LIBTAYO's robust efficacy in high-risk CSCC ... The cost for a supply of 7mL for IV infusion is $11,178. While this is a very rough estimate, sales of a single vial of the drug to 10% of the ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...

Regeneron Pharmaceuticals on Monday presented positive Phase III data for its PD-1 inhibitor Libtayo, which yielded significant survival benefits when used as an adjuvant treatment for patients with ...

The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary measure of success, disease-free survival (DFS), showed significant ...

Fianlimab (LAG3) for melanoma: Combining fianlimab and Libtayo, two potentially best-in-class checkpoint inhibitors, has the potential for differentiated efficacy and safety versus the current ...